"Radiopharmaceuticals" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161)
| Descriptor ID |
D019275
|
| MeSH Number(s) |
D27.505.259.843 D27.505.519.871 D27.720.470.410.650
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Radiopharmaceuticals".
Below are MeSH descriptors whose meaning is more specific than "Radiopharmaceuticals".
This graph shows the total number of publications written about "Radiopharmaceuticals" by people in this website by year, and whether "Radiopharmaceuticals" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 2 | 1 | 3 |
| 1999 | 1 | 0 | 1 |
| 2000 | 1 | 1 | 2 |
| 2001 | 1 | 3 | 4 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 5 | 5 |
| 2004 | 2 | 4 | 6 |
| 2005 | 2 | 1 | 3 |
| 2006 | 2 | 6 | 8 |
| 2007 | 2 | 3 | 5 |
| 2008 | 0 | 4 | 4 |
| 2009 | 0 | 3 | 3 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 2 | 3 |
| 2012 | 1 | 3 | 4 |
| 2013 | 0 | 2 | 2 |
| 2014 | 2 | 2 | 4 |
| 2015 | 2 | 4 | 6 |
| 2016 | 1 | 2 | 3 |
| 2017 | 2 | 4 | 6 |
| 2018 | 1 | 3 | 4 |
| 2019 | 2 | 0 | 2 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 7 | 7 |
| 2022 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Radiopharmaceuticals" by people in Profiles.
-
Monitoring Therapeutic Responses to Silicified Cancer Cell Immunotherapy Using PET/MRI in a Mouse Model of Disseminated Ovarian Cancer. Int J Mol Sci. 2022 Sep 10; 23(18).
-
The increasing indications of FDG-PET/CT in the staging and management of Invasive Bladder Cancer. Urol Oncol. 2022 10; 40(10):434-441.
-
Recent advances in the treatment of advanced prostate cancer: maximizing existing therapies while searching for novel solutions. Curr Opin Oncol. 2022 05 01; 34(3):228-233.
-
Tumorous tissue characterization using integrated 18F-FDG PET/dual-energy CT in lung cancer: Combining iodine enhancement and glycolytic activity. Eur J Radiol. 2022 May; 150:110116.
-
Risk of Radiation Exposure to Clinical Staff from Paracenteses of Large-Volume Chylous Ascites After 177Lu-DOTATATE Infusion. J Nucl Med Technol. 2022 Sep; 50(3):274-277.
-
Prospective Evaluation of the First Integrated Positron Emission Tomography/Dual-Energy Computed Tomography System in Patients With Lung Cancer. J Thorac Imaging. 2021 Nov 01; 36(6):382-388.
-
Cytokine Signaling and Matrix Remodeling Pathways Associated with Cardiac Sarcoidosis Disease Activity Defined Using FDG PET Imaging. Int Heart J. 2021 Sep 30; 62(5):1096-1105.
-
Highlighting recent treatment advances in metastatic prostate cancer: expanding the treatment arsenal. Curr Opin Oncol. 2021 05 01; 33(3):252-256.
-
U.S. Diagnostic Reference Levels and Achievable Administered Activities for Adult Renal Scintigraphy: An Analysis of the Intersocietal Accreditation Committee Nuclear Laboratories. J Nucl Med Technol. 2021 Sep; 49(3):246-249.
-
Antiseptic-Mediated Colloid Labeling as a Potential Source of Abnormal Liver and Spleen Uptake with 99mTc-Dimercaptosuccinic Acid. J Nucl Med Technol. 2021 Sep; 49(3):290-291.